First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study

[1]  P. Scardino,et al.  MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. , 2022, The Lancet. Oncology.

[2]  J. Fütterer,et al.  Real-Time MRI-Guided Prostate Interventions , 2022, Cancers.

[3]  R. Sroka,et al.  Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA). , 2021, Urologic oncology.

[4]  J. Bomers,et al.  Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer , 2021, Journal of Urology.

[5]  A. Burnett,et al.  The Quality of Life and Economic Burden of Erectile Dysfunction , 2021, Research and reports in urology.

[6]  P. Taimen,et al.  Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer , 2020, Acta radiologica.

[7]  P. Taimen,et al.  Salvage Magnetic Resonance Imaging–guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results , 2020, European urology open science.

[8]  J. Chin,et al.  Magnetic resonance imaging‐guided transurethral ultrasound ablation in patients with localised prostate cancer: 3‐year outcomes of a prospective Phase I study , 2020, BJU International.

[9]  J. Chin,et al.  Relief of Lower Urinary Tract Symptoms after MRI-Guided Transurethral Ultrasound Ablation (TULSA) for localized prostate cancer: Subgroup Analyses in Patients with concurrent cancer and Benign Prostatic Hyperplasia. , 2020, Journal of endourology.

[10]  P. Taimen,et al.  Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer , 2020, Scandinavian journal of urology.

[11]  H. Lepor,et al.  Oncological control following partial gland ablation for intermediate-risk prostate cancer. , 2020, Urologic oncology.

[12]  J. Chin,et al.  Salvage open radical prostatectomy for recurrent prostate cancer following MRI-guided transurethral ultrasound ablation (TULSA) of the prostate: feasibility and efficacy , 2020, Scandinavian journal of urology.

[13]  D. Penson,et al.  Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial. , 2020, Journal of vascular and interventional radiology : JVIR.

[14]  H. Ahmed,et al.  Evaluating the Trade-offs Men with Localised Prostate Cancer Make Between the Risks and Benefits of Treatments: The COMPARE Study. , 2020, The Journal of urology.

[15]  P. Taimen,et al.  Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer , 2019, Scandinavian journal of urology.

[16]  J. Chin,et al.  Relief of lower urinary tract symptoms after MRI-guided transurethral ultrasound ablation (TULSA): Subgroup analyses in patients with symptoms of benign prostatic hyperplasia , 2019, European Urology Supplements.

[17]  Raj Persad,et al.  A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer , 2018, European urology.

[18]  David Bonekamp,et al.  Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate , 2018, European Radiology.

[19]  T. D. de Reijke,et al.  Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation. , 2017, European urology focus.

[20]  Cesare Romagnoli,et al.  Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial. , 2016, European urology.

[21]  Heather Cadieux-Pitre,et al.  Magnetic resonance image guided transurethral ultrasound prostate ablation: a preclinical safety and feasibility study with 28-day followup. , 2015, The Journal of urology.

[22]  J. Fütterer,et al.  Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project , 2015, World Journal of Urology.

[23]  Hashim Uddin Ahmed,et al.  The index lesion and the origin of prostate cancer. , 2009, The New England journal of medicine.

[24]  John T. Wei,et al.  Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H M Sandler,et al.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.

[26]  Mark Emberton,et al.  New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. , 2017, European urology.

[27]  H. Ahmed,et al.  Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. , 2017, Urologic oncology.

[28]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..